Cargando…

Brain hypoxia, neurocognitive impairment, and quality of life in people post-COVID-19

OBJECTIVE: Systemic hypoxia occurs in COVID-19 infection; however, it is unknown if cerebral hypoxia occurs in convalescent individuals. We have evidence from other conditions associated with central nervous system inflammation that hypoxia may occur in the brain. If so, hypoxia could reduce the qua...

Descripción completa

Detalles Bibliográficos
Autores principales: Adingupu, Damilola D., Soroush, Ateyeh, Hansen, Ayden, Twomey, Rosie, Dunn, Jeff F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10200033/
https://www.ncbi.nlm.nih.gov/pubmed/37210689
http://dx.doi.org/10.1007/s00415-023-11767-2
_version_ 1785045053659414528
author Adingupu, Damilola D.
Soroush, Ateyeh
Hansen, Ayden
Twomey, Rosie
Dunn, Jeff F.
author_facet Adingupu, Damilola D.
Soroush, Ateyeh
Hansen, Ayden
Twomey, Rosie
Dunn, Jeff F.
author_sort Adingupu, Damilola D.
collection PubMed
description OBJECTIVE: Systemic hypoxia occurs in COVID-19 infection; however, it is unknown if cerebral hypoxia occurs in convalescent individuals. We have evidence from other conditions associated with central nervous system inflammation that hypoxia may occur in the brain. If so, hypoxia could reduce the quality of life and brain function. This study was undertaken to assess if brain hypoxia occurs in individuals after recovery from acute COVID-19 infection and if this hypoxia is associated with neurocognitive impairment and reduced quality of life. METHODS: Using frequency-domain near-infrared spectroscopy (fdNIRS), we measured cerebral tissue oxygen saturation (S(t)O(2)) (a measure of hypoxia) in participants who had contracted COVID-19 at least 8 weeks prior to the study visit and healthy controls. We also conducted neuropsychological assessments and health-related quality of life assessments, fatigue, and depression. RESULTS: Fifty-six percent of the post-COVID-19 participants self-reported having persistent symptoms (from a list of 18), with the most reported symptom being fatigue and brain fog. There was a gradation in the decrease of oxyhemoglobin between controls, and normoxic and hypoxic post-COVID-19 groups (31.7 ± 8.3 μM, 27.8 ± 7.0 μM and 21.1 ± 7.2 μM, respectively, p = 0.028, p = 0.005, and p = 0.081). We detected that 24% of convalescent individuals’ post-COVID-19 infection had reduced S(t)O(2) in the brain and that this relates to reduced neurological function and quality of life. INTERPRETATION: We believe that the hypoxia reported here will have health consequences for these individuals, and this is reflected in the correlation of hypoxia with greater symptomology. With the fdNIRS technology, combined with neuropsychological assessment, we may be able to identify individuals at risk of hypoxia-related symptomology and target individuals that are likely to respond to treatments aimed at improving cerebral oxygenation.
format Online
Article
Text
id pubmed-10200033
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-102000332023-05-23 Brain hypoxia, neurocognitive impairment, and quality of life in people post-COVID-19 Adingupu, Damilola D. Soroush, Ateyeh Hansen, Ayden Twomey, Rosie Dunn, Jeff F. J Neurol Original Communication OBJECTIVE: Systemic hypoxia occurs in COVID-19 infection; however, it is unknown if cerebral hypoxia occurs in convalescent individuals. We have evidence from other conditions associated with central nervous system inflammation that hypoxia may occur in the brain. If so, hypoxia could reduce the quality of life and brain function. This study was undertaken to assess if brain hypoxia occurs in individuals after recovery from acute COVID-19 infection and if this hypoxia is associated with neurocognitive impairment and reduced quality of life. METHODS: Using frequency-domain near-infrared spectroscopy (fdNIRS), we measured cerebral tissue oxygen saturation (S(t)O(2)) (a measure of hypoxia) in participants who had contracted COVID-19 at least 8 weeks prior to the study visit and healthy controls. We also conducted neuropsychological assessments and health-related quality of life assessments, fatigue, and depression. RESULTS: Fifty-six percent of the post-COVID-19 participants self-reported having persistent symptoms (from a list of 18), with the most reported symptom being fatigue and brain fog. There was a gradation in the decrease of oxyhemoglobin between controls, and normoxic and hypoxic post-COVID-19 groups (31.7 ± 8.3 μM, 27.8 ± 7.0 μM and 21.1 ± 7.2 μM, respectively, p = 0.028, p = 0.005, and p = 0.081). We detected that 24% of convalescent individuals’ post-COVID-19 infection had reduced S(t)O(2) in the brain and that this relates to reduced neurological function and quality of life. INTERPRETATION: We believe that the hypoxia reported here will have health consequences for these individuals, and this is reflected in the correlation of hypoxia with greater symptomology. With the fdNIRS technology, combined with neuropsychological assessment, we may be able to identify individuals at risk of hypoxia-related symptomology and target individuals that are likely to respond to treatments aimed at improving cerebral oxygenation. Springer Berlin Heidelberg 2023-05-21 2023 /pmc/articles/PMC10200033/ /pubmed/37210689 http://dx.doi.org/10.1007/s00415-023-11767-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Communication
Adingupu, Damilola D.
Soroush, Ateyeh
Hansen, Ayden
Twomey, Rosie
Dunn, Jeff F.
Brain hypoxia, neurocognitive impairment, and quality of life in people post-COVID-19
title Brain hypoxia, neurocognitive impairment, and quality of life in people post-COVID-19
title_full Brain hypoxia, neurocognitive impairment, and quality of life in people post-COVID-19
title_fullStr Brain hypoxia, neurocognitive impairment, and quality of life in people post-COVID-19
title_full_unstemmed Brain hypoxia, neurocognitive impairment, and quality of life in people post-COVID-19
title_short Brain hypoxia, neurocognitive impairment, and quality of life in people post-COVID-19
title_sort brain hypoxia, neurocognitive impairment, and quality of life in people post-covid-19
topic Original Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10200033/
https://www.ncbi.nlm.nih.gov/pubmed/37210689
http://dx.doi.org/10.1007/s00415-023-11767-2
work_keys_str_mv AT adingupudamilolad brainhypoxianeurocognitiveimpairmentandqualityoflifeinpeoplepostcovid19
AT soroushateyeh brainhypoxianeurocognitiveimpairmentandqualityoflifeinpeoplepostcovid19
AT hansenayden brainhypoxianeurocognitiveimpairmentandqualityoflifeinpeoplepostcovid19
AT twomeyrosie brainhypoxianeurocognitiveimpairmentandqualityoflifeinpeoplepostcovid19
AT dunnjefff brainhypoxianeurocognitiveimpairmentandqualityoflifeinpeoplepostcovid19